Results 261 to 270 of about 156,514 (326)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Effectiveness of conditioning + open-label placebo for post-operative pain management in adolescent idiopathic scoliosis. [PDF]

Pain Manag
Furie KS, James K, Kaptchuk TJ, Diab M.
europepmc   +1 more source

A worthwhile wager: the ethics of open-label placebo treatment in clinical practice [PDF]

Doug Hardman, Franklin G. Miller
openalex   +1 more source

Itopride in functional dyspepsia: open-label, 1-year treatment follow-up of two multicenter, randomized, double-blind, placebo-controlled trials

Bert Broeders, Jan Tack, Nicholas J. Talley   +2 more
openalex   +1 more source

Effects of pyrimethamine versus proguanil in malarial chemoprophylaxis in children with sickle cell disease: a randomized, placebo-controlled, open-label study

, 2003
Felicia U. Eke, Ifeoma Anochie
openalex   +2 more sources

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Use of DNA profiling to resolve HIV status in a person using injectable cabotegravir for HIV pre-exposure prophylaxis. [PDF]

J Clin Pathol
Fogel JM, Salih MA, Haddaway K, Marzinke MA, Marshall C, Wang Z, Cummings V, Piwowar-Manning E, Rooney JF, McCauley M, Grinsztejn B, Landovitz RJ, Eshleman SH.   +12 more
europepmc   +1 more source

Justice for Placebo: Placebo Effect in Clinical Trials and Everyday Practice. [PDF]

Medicines (Basel)
Knezevic NN, Sic A, Worobey S, Knezevic E.   +3 more
europepmc   +1 more source

L‐Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications

Epilepsia, EarlyView.
Abstract Objective Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power.
Wesley T. Kerr, Neo Kok, Katherine N. McFarlane, Advith S. Reddy, Lavanya Biju, Jacqueline A. French, Daniel M. Goldenholz   +6 more
wiley   +1 more source

A systematic review and meta analysis of open label placebo effects in chronic musculoskeletal pain. [PDF]

Sci Rep
Borg F, Gedin F, Franzén E, Grooten WJA.   +3 more
europepmc   +1 more source